Bharat Biotech had on Monday applied to the central drug regulator seeking emergency use authorisation for its COVID-19 vaccine Covaxin.Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).The Hyderabad-based firm is conducting phase-3 clinical trial of its vaccine in around 25 places, including Delhi, Mumbai, Patna and Lucknow.The firm, while applying for the phase-3 trial, had stated that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported.Bhushan also said that Drugs Controller General of India could grant a license to some developers of Covid-19 vaccines in the next few weeks.Six vaccines, including AstraZeneca's.